Sagimet Biosciences
PublicSagimet Biosciences is now publicly traded
The data on this page reflects Sagimet Biosciences's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jul 13, 2023
Last Round
Follow-on Offering
Jan 25, 2024
Total Funding Raised
$399.4M
Company Overview
Sagimet Biosciences operates in Healthcare and is based in San Mateo, California. Its recorded funding history includes a Growth Equity round in February 2021.
Sagimet Biosciences (NAS: SGMT) is a biopharmaceutical company dedicated to developing selective fatty acid synthase (FASN) inhibitors for treating diseases linked to dysfunctional lipid metabolism, with its lead candidate, denifanstat, being an oral medication aimed at nonalcoholic steatohepatitis (NASH).
Sector
Healthcare
AI Layer
Non-AI
Sagimet Biosciences Comparables
Compare Sagimet Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Galea Therapeutics | 75% | |
| NorthSea Therapeutics | 72% | |
| OrsoBio | 70% |
For institutional investors. Book with your work email.
Sagimet Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Jan 25, 2024 | ||||
| IPO | Jul 13, 2023 | ||||
| Growth Equity | Feb 11, 2021 | ||||
| Series E | Aug 5, 2019 | ||||
| Series D | Dec 30, 2014 | ||||
Series C | Jun 21, 2013 |
For institutional investors. Book with your work email.
Sagimet Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series B, Series C, Series A |
| New Enterprise Associates | Series E, Growth Equity, Series B, Series C, Series D |
| Ally Bridge Group | Series D |
| Altium Capital | Growth Equity |
| The Chernin Group | Series B, Series A |
| TD Cowen | Follow-on Offering |
| HM Capital | Growth Equity |
For institutional investors. Book with your work email.
Sagimet Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.